Paper Details

  1. Home
  2. Paper Details

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

Author: AttenoMariangela, CasoFrancesco, CostaLuisa, Del PuenteAntonio, IervolinoSalvatore, LubranoEnnio, PadulaStefania, PelusoRosario, SanduzziAlessandro, ScarpaRaffaele

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effectiveness and safety of three medications for psoriatic arthritis (PsA) in people who had not responded well to previous treatments: Infliximab (INF), Etanercept (ETN), and Adalimumab (ADA). All three medications significantly improved PsA symptoms, but each had unique benefits. ETN showed the greatest improvement in joint tenderness and disability, while INF and ADA showed the most improvement in skin lesions. Side effects were reported in 15% of patients, with only two considered drug-related (pneumonitis and low platelet count) in those taking INF. This study suggests that these medications effectively treat PsA, but understanding their individual strengths may help optimize treatment choices.
Paper Details　
Original Abstract of the Article :
The aim of this study is to compare effectiveness and safety of Infliximab (INF), Etanercept (ETN), and Adalimumab (ADA) in patients with psoriatic arthritis (PsA) with inadequate response to a previous disease-modifying antirheumatic drug (DMARD). One hundred consecutive PsA patients with inadequat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10067-009-1340-7

データ提供：米国国立医学図書館（NLM）

Psoriatic Arthritis: A Comparison of TNF-alpha Blockers

Psoriatic arthritis is a complex and often debilitating condition that can significantly impact a person's quality of life. This research compares the effectiveness and safety of three TNF-alpha blockers: infliximab, etanercept, and adalimumab, in patients with psoriatic arthritis who have not responded well to previous treatments. It's like comparing different maps to navigate the desert of psoriatic arthritis, seeking the most effective path to relief.

The researchers used [research methods] to assess the clinical and laboratory outcomes in patients receiving these TNF-alpha blockers. Their findings suggest that all three drugs effectively controlled signs and symptoms of psoriatic arthritis, offering a range of options for patients who have not responded to other treatments.

Finding the Right Path in the Desert of Psoriatic Arthritis

The study indicates that TNF-alpha blockers, like different routes through a desert, can offer effective relief from the challenges of psoriatic arthritis. The findings suggest that different medications have distinct profiles, allowing clinicians to choose the best option for individual patients.

Navigating the Desert of Psoriatic Arthritis Treatment

This research highlights the importance of careful patient selection and medication choice in treating psoriatic arthritis. It's like selecting the right camel for your journey through the desert, ensuring you have the best chance of successfully navigating the terrain. By understanding the different profiles of available medications, clinicians can provide more personalized care and help patients find the most effective treatment options.

Dr.Camel's Conclusion

This study provides valuable insights into the effectiveness and safety of TNF-alpha blockers in treating psoriatic arthritis. It's a reminder that even in the seemingly vast and unchanging desert of medicine, new treatments and strategies are constantly emerging, offering hope for a better future for patients with this challenging condition.

Date :
  1. Date Completed 2010-05-27
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

20066450

DOI: Digital Object Identifier

10.1007/s10067-009-1340-7

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.